share_log

Marijuana Company of America Appoints Marco Guerrero to new role as hempSMART Advisor Guerrero to Guide South American Distribution of hempSMART(TM) Products

Marijuana Company of America Appoints Marco Guerrero to new role as hempSMART Advisor Guerrero to Guide South American Distribution of hempSMART(TM) Products

美国大麻公司任命马尔科·格雷罗担任hempSMART顾问格雷罗,指导hempSMART(商标)产品在南美的分销
Accesswire ·  2022/07/12 18:05

LOS ANGELES, CA / ACCESSWIRE / July 12, 2022 / Marijuana Company of America Inc. ("MCOA" or the "Company") (OTC PINK:MCOA), an innovative hemp and cannabis corporation, today announced the appointment of former director Marco Guerrero as special advisor to the Company's hempSMART™ South American division.

加利福尼亚州洛杉矶/ACCESSWIRE/2022年7月12日/ 美国大麻公司。("MCOA“或”公司)(场外交易市场代码:MCOA),一家创新的大麻和大麻公司,今天宣布任命前董事公司的马尔科·格雷罗为公司的HempSMART™南美部的特别顾问。

MCOA's Latin American hempSMART™ joint venture currently serves medical users in Brazil, who buy hemp-derived CBD hempSMART™ products by prescription from Brazilian physicians. Brazil, a country with a population of over 212 million consumers, buys CBD in rapidly expanding quantities. MCOA intends to expand our consumer base by delivering more of our high-quality hempSMART™ product portfolio to Brazil and other Latin American countries.

MCoA在拉丁美洲的合资公司hempSMART™目前为巴西的医疗用户提供服务,这些用户通过巴西医生的处方购买大麻衍生的cbd hempSMART™产品。拥有超过2.12亿消费者的巴西,购买CBD的数量迅速增加。MCOA打算通过向巴西和其他拉美国家提供更多高质量的hempSMART™产品组合来扩大我们的消费者基础。

Mr. Guerrero stepped down from MCOA's Board of Directors on July 1, 2022, to work with the Company as a non-executive advisor to our wholly-owned subsidiary Hempsmart Global, Inc., the parent company of MCOA's Latin American hempSMART™ joint venture. This new position will require him to focus exclusively on penetrating the Brazilian market. Consequently, there was a mutual agreement to have Marco step down as a director of MCOA.

格雷罗先生于2022年7月1日从MCOA董事会辞职,与公司一起工作,担任我们的全资子公司HempSmart Global,Inc.的非执行顾问,HempSmart Global,Inc.是MCOA在拉丁美洲的HempSMART™合资企业的母公司。这一新职位将要求他专注于渗透巴西市场。结果,双方达成协议,让马可辞去马可在董事的职务。

Jesus M. Quintero, CEO, and CFO of MCOA stated, "Our joint venture in Brazil is building a solid base for our sales of hempSMART™ product line in Brazil and other significant South American markets, and is a major strategic partnership for MCOA. Brazil, with a sales potential of hundreds of millions of consumers, is central to our vision for expansion. While the US CBD market has matured and is saturated with brands, we believe there is an early market entrant advantage for us entering the market with our established hempSMART brand. Marco Guerrero is building out our South American framework and adding him as a special advisor to that MCOA division further aligns our focus on increasing sales in the region. We are focused on the opportunity for significant market penetration in the expanding Brazilian CBD market."

MCOA首席执行官兼首席财务官Jesse M.Quintero表示:“我们在巴西的合资企业为我们在巴西和其他重要的南美市场销售hempSMART™产品系列奠定了坚实的基础,也是MCOA的重要战略合作伙伴关系。巴西拥有数亿消费者的销售潜力,是我们扩张愿景的核心。虽然美国CBD市场已经成熟,品牌已经饱和,但我们相信,对于我们来说,凭借我们成熟的hempSMART品牌进入市场具有早期的市场进入者优势。Marco Guerrero正在建立我们的南美框架,并将他作为MCOA部门的特别顾问,进一步调整我们对增加该地区销售的关注。我们专注于在不断扩大的巴西中央商务区市场获得重大市场渗透的机会。“

About Marijuana Company of America, Inc.

关于美国大麻公司。

MCOA is a corporation that participates in: (1) product research and development of legal hemp-based consumer products under the brand name "hempSMART™", which targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

MCoA是一家参与以下活动的公司:(1)“hempSMART™”品牌下合法大麻消费产品的产品研发,目标是大众的健康和福祉;(2)关联营销计划,以推广和销售其含有CBD的合法大麻消费产品;(3)随着合法市场的成熟和发展,其业务扩展到合法大麻和大麻行业的辅助领域。

About Hempsmart Brazil

关于汉普斯马特巴西

MCOA controls

MCOA控制

About our hempSMART Products Containing CBD

关于我们包含CBD的hempSMART产品

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is an effective treatment for any medical condition as drugs or dietary supplements subject to the FDA's jurisdiction.

美国食品和药物管理局(FDA)尚未承认CBD是任何适应症的安全有效的药物。我们的产品含有从工业大麻中提取的CBD,其销售或销售并不是基于将其用作受FDA管辖的药物或膳食补充剂的任何医疗疾病的有效治疗。

Forward-Looking Statements

前瞻性陈述

This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q, and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

本新闻稿包含并非纯粹历史性的“前瞻性陈述”,可能包括有关对未来的信念、计划、期望或意图的任何陈述。此类前瞻性表述包括新商机的发展、成本和结果,以及诸如“预期”、“寻求”、“打算”、“相信”、“估计”、“预期”、“项目”、“计划”等词汇,或类似的表述可被视为1995年“私人证券诉讼改革法”所指的“前瞻性表述”。由于许多因素,实际结果可能与任何前瞻性陈述中预测的结果不同。这些因素包括与新项目相关的固有不确定性、未来美国和全球经济、竞争的影响,以及该公司对现有法规的依赖,这些法规涉及大麻产品的使用和开发。这些前瞻性陈述是截至本新闻稿发布之日作出的,我们没有义务更新前瞻性陈述,也没有义务更新实际结果可能与前瞻性陈述中预测的结果不同的原因。尽管我们相信本新闻稿中包含的任何信念、计划、预期和意图都是合理的,但不能保证任何此类信念、计划、预期或意图将被证明是准确的。投资者应参考此处列出的所有信息,也应参考我们的年度报告Form 10-K、我们的Form 10-Q季度报告以及不时提交给美国证券交易委员会的其他定期报告中概述的风险因素披露。欲了解更多信息,请访问Www.sec.gov.

CONTACT:

联系方式:

info@marijuanacompanyofamerica.com
info@mcoainvestments.com
888-777-4362

邮箱:info@marijuanacompanyofamerica.com
邮箱:Info@mcoainvestments.com
888-777-4362

SOURCE: Marijuana Company of America, Inc.

资料来源:美国大麻公司。


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发